This article is in the news archive.
Cambridge study has major implications for the potential treatment of PD
Parkinson’s disease (PD) is a neurodegenerative disorder that results in the loss of nigrostriatal dopamine neurons. The etiology of this cell loss is unknown, but it involves abnormalities in mitochondrial function. A recent collaborative study, from the laboratories of Professor John Sinclair (Department of Medicine) and Cambridge neuroscientist Dr Roger Barker (Cambridge Centre for Brain Repair), has demonstrated that the administration of a novel noncoding p137 RNA, derived from the human cytomegaloviral β2.7 transcript, can prevent and rescue dopaminergic cell death in vitro and in animal models of PD by protecting mitochondrial Complex I activity. Furthermore, as this p137 RNA is fused to a rabies virus glycoprotein peptide that facilitates delivery of RNA across the blood–brain barrier, such protection can be achieved through a peripheral intravenous administration of this agent after the initiation of a dopaminergic lesion.
This approach has major implications for the potential treatment of PD, especially given that this novel agent could have the same protective effect on all diseased neurons affected as part of this disease process, not just the dopaminergic nigrostriatal pathway.
Cambridge neuroscientist Wei-Li Kuan was the lead author on this article which was published in the Journal of Experimental Medicine.
Posted on Thursday 12 January, 2012
Go to the news index page.